Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Eli Lilly’s (NYSE:LLY) experimental obesity therapy eloralintide has caused up to 11% weight loss over 12 weeks in an ...

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound. For many consumers, their insurance denies them coverage for weight loss drugs. Now, for those who have to pay out-of ...

Mounjaro is a diabetes drug, and FDA approved Zepbound for weight loss last year. Its main competitor, Wegovy, is still in shortage. Tags drug shortages Eli Lilly fda GLP-1 ...

April 17 (UPI) --People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its latest clinical testing, the Indianapolis-based drugmaker ...

Patients on the drug lost a lot of weight — lowering their risk of developing diabetes The weight loss benefits of taking Eli Lilly's dual-agonist drug, (generically called tirzepatide ...

Those results helped the drug receive its Food and Drug Administration approval for weight loss last year. Eli Lilly submitted data for tirzepatide as a treatment for moderate-to-severe ...

Eli Lilly has finally made enough supply of its popular medicine tirzepatide to meet soaring demand, which should help the company widen its share of the booming weight-loss drug market.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and ... to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against ...

The article has been corrected. The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday. Eli Lilly’s ...